Advaxis - Stock Price History | ADXS
Historical daily share price chart and data for Advaxis since 2021 adjusted for splits. The latest closing stock price for Advaxis as of October 27, 2021 is 0.49.
- The all-time high Advaxis stock closing price was 937.03 on July 29, 2005.
- The Advaxis 52-week high stock price is 1.57, which is 220.4% above the current share price.
- The Advaxis 52-week low stock price is 0.26, which is 46.9% below the current share price.
- The average Advaxis stock price for the last 52 weeks is 0.54.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Advaxis Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2020 |
0.6037 |
1.0900 |
1.3000 |
0.2840 |
0.3487 |
-59.34% |
| 2019 |
2.4571 |
4.4228 |
7.6012 |
0.2485 |
0.8577 |
-69.89% |
| 2018 |
22.4771 |
46.4768 |
48.5757 |
2.7811 |
2.8486 |
-93.31% |
| 2017 |
97.2542 |
112.2939 |
143.9280 |
42.2789 |
42.5787 |
-60.34% |
| 2016 |
134.3328 |
141.0795 |
239.5802 |
81.8591 |
107.3463 |
-28.83% |
| 2015 |
221.1246 |
126.2369 |
431.3343 |
105.2474 |
150.8246 |
25.59% |
| 2014 |
54.2950 |
61.1694 |
134.9325 |
37.6312 |
120.0900 |
88.92% |
| 2013 |
97.5185 |
56.2219 |
262.3688 |
40.4798 |
63.5682 |
13.07% |
| 2012 |
175.1124 |
299.8501 |
318.5907 |
56.2219 |
56.2219 |
-81.25% |
| 2011 |
279.1759 |
224.8876 |
449.7751 |
224.8876 |
299.8501 |
33.33% |
| 2010 |
294.9418 |
243.6282 |
431.0345 |
187.4063 |
224.8876 |
-14.29% |
| 2009 |
159.5928 |
37.4813 |
318.5907 |
37.4813 |
262.3688 |
600.00% |
| 2008 |
151.5991 |
318.5907 |
318.5907 |
24.3628 |
37.4813 |
-88.24% |
| 2007 |
429.7652 |
374.8126 |
805.8471 |
262.3688 |
318.5907 |
-5.56% |
| 2006 |
406.8434 |
393.5532 |
562.2189 |
262.3688 |
337.3313 |
-14.29% |
| 2005 |
461.6384 |
843.3283 |
937.0315 |
299.8501 |
393.5532 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.072B |
$0.000B |
|
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
|
